Apogee Therapeutics, Inc. (APGE)
$135.07-0.01%Close
BUYBULL · day 49
Key stats
- Market cap
- $8.4B
- Beta
- 0.34
- P/E (TTM)
- -31.12
- 1W
- +0.09%
- 1M
- +0.66%
- vs SPY 1W
- -0.33%
- vs SPY 1M
- -1.40%
Industry peers
FMP comparable companies · ranked by market cap
- CNTACentessa Pharmaceuticals plc$6.3B$40.50
- CGONSELLCG Oncology Inc.$5.5BCRISISQ 25$62.38-1.16%
- LEGNSELLLegend Biotech Corporation$3.5BRECOVERYQ 2$19.12+0.45%
- XENESELLXenon Pharmaceuticals Inc.$3.5BCRISISQ 22$36.41-3.88%
- CELCSELLCelcuity Inc.$3.2BCRISISQ 26$65.78-4.04%
- ZLABSELLZai Lab Limited$2.9BCRISISQ 8$25.31-6.06%
- SLNOSoleno Therapeutics, Inc.$2.8B$53.01
- IRONSELLDisc Medicine, Inc.$2.3BCRISISQ 1$61.18-6.42%
- RAREBUYUltragenyx Pharmaceutical Inc.$1.5BRECOVERYQ -6$14.89-2.48%
- AAPGSELLAscentage Pharma Group International$1.4BCRISISQ 5$14.94-1.63%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on APGE?
- LOPJLB’s latest quantitative signal on Apogee Therapeutics, Inc. (APGE) is BUY in a BULL regime. Signals are updated daily.
- What market regime is APGE in?
- Apogee Therapeutics, Inc. (APGE) is currently classified in the BULL HMM market regime on LOPJLB.
- What does Apogee Therapeutics, Inc. (APGE) do?
- Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life…